Interprovider Variation in Initiation of Bone-Modifying Agents for Patients With Prostate Cancer
BMA overuse in mCSPC was rare, potentially reflecting de-implementation following evidence of lack of benefit. Appropriate BMA use for patients with mCRPC varies substantially among clinicians and health care systems. Interventions to increase guideline-concordant care may improve outcomes.
Authors
- Michael J. Morris (ORCID: https://orcid.org/0000-0002-9454-0096)
- Aaron Philip Mitchell (ORCID: https://orcid.org/0000-0003-3639-3515)
- Azeez Farooki (ORCID: https://orcid.org/0000-0003-4508-5186)
- Jamie S. Ostroff (ORCID: https://orcid.org/0000-0003-2671-5680)
- Nirjhar Chakraborty (ORCID: https://orcid.org/0009-0003-8104-4311)
- Allison Lipitz‐Snyderman (ORCID: https://orcid.org/0000-0003-2423-2220)
- Andrew Salner (ORCID: https://orcid.org/0000-0002-3145-2953)
- Paul Palyca
- Sonia Persaud (ORCID: https://orcid.org/0009-0008-5666-7994)
- Anis Hamid (ORCID: https://orcid.org/0000-0002-7193-9723)
- Michael Leapman (ORCID: https://orcid.org/0000-0002-0727-7614)
- Michaela A. Dinan (ORCID: https://orcid.org/0000-0003-4849-4743)
- Dedipya Bhamidipati (ORCID: https://orcid.org/0009-0002-6604-9053)
- Maria Klimchuk (ORCID: https://orcid.org/0009-0004-8821-2741)
Institutions
- Hartford Hospital (US)
- Lehigh Valley Hospital-Pocono (US)
- Memorial Sloan Kettering Cancer Center (US)
- University of Pittsburgh (US)
- SUNY Downstate Health Sciences University (US)
- Cornell University (US)
- Yale Cancer Center (US)
- Yale University (US)
- Weill Cornell Medicine (US)
- Hartford Financial Services (United States)
Publication Details
- Journal
- JCO Oncology Practice
- Published
- 2025-11-03
- DOI
- https://doi.org/10.1200/op-25-00457
- Primary Topic
- Bone health and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00